Abstract-Activation of peroxisome proliferator-activated receptors (PPARs), namely PPARc and PPARd, has been shown to provide neuroprotection in a number of neurodegenerative disorders, such as Alzheimer's and Parkinson's disease (PD). The observed neuroprotective effects in experimental models of PD have been linked to anti-oxidant and anti-inflammatory actions. This study aimed to analyze the full influence of these receptors in neuroprotection by generating a nerve cell-specific conditional knock-out of these receptors and subjecting these genetically modified mice to the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin to model dopaminergic degeneration. Mice null for both receptors show the lowest levels of tyrosine hydroxylase (TH)-positive cell bodies following MPTP administration. Presence of one or both these receptors show a trend toward protection against this degeneration, as higher dopaminergic cell immunoreactivity and striatal monoamine levels are evident. These data supplement recent studies that have elected to use agonists of the receptors to regulate immune responses. The results place further importance on the activation of PPARs and the neuroprotective roles these have in inflammatory processes linked to neurodegenerative processes. Ó
INTRODUCTION
Peroxisome proliferator-activated receptors (PPARs) are a family of nuclear ligand-activated transcription factors controlling a variety of genes with roles in lipid metabolism, insulin sensitivity, fatty acid transport and regulation of inflammation. They do this by binding to specific peroxisome proliferator response elements in enhancer sites of target genes. Initially identified in Xenopus laevis, there are three mammalian isoformsPPARa, PPARd and PPARc -each with different tissue expression patterns and ligand affinities (Desvergne and Wahli, 1999 ).
Parkinson's disease (PD) is a chronic progressive disorder, characterized by the loss of dopaminergic neurons in the nigrostriatal pathway (Dauer and Przedborski, 2004) , with symptoms including bradykinesia, resting tremor and postural instability. This pattern of cell death can be reliably replicated using the 1-met hyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin. In the majority of cases the cause of the disease is unknown, while the full pathology of the disease is not understood. However, certain processes have been implicated in the death of neurons, including inflammation, as shown through increased glial activity and astrogliosis in PD brains (McGeer et al., 1988) , while MPTP also causes pathogenic upregulation of the immune response (Kurkowska-Jastrzebska et al., 1999) . PPARc agonists provided neuroprotection in the MPTP (Breidert et al., 2002; Dehmer et al., 2004; Lecca et al., 2015; Pisanu et al., 2014; Barbiero et al., 2014) and 6-hydroxydopamine (6-OHDA) model of PD (Laloux et al., 2012; Sadeghian et al., 2012) . The PPARc agonist pioglitazone has been shown to inhibit MPTP-and lipopolysaccharide (LPS)-induced neuronal nuclear factor kappaB activation (Dehmer et al., 2004; Lecca et al., 2015) , and PPARc agonists reduced MPTP-induced tumor necrosis factor-alpha (TNF-a and interleukin (IL)-1b expression (Pisanu et al., 2014) , and LPS-induced neuronal cyclo-oxygenase-2, TNF-a, IL1b and IL-6 expression, thus providing protection (Luna-Medina et al., 2005) .
However, the picture is not quite as clear for PPARd, as an agonist of this receptor had no effect in the 6-OHDA model (Sadeghian et al., 2012) neuroprotection in the MPTP-model of PD (Iwashita et al., 2007; Martin et al., 2013) . In general, PPARd agonists seem to be capable of protecting against oxidative stress and neuroinflammation (reviewed in (Schnegg and Robbins, 2011) ).
Herein, we wanted to address the role of neuronal PPAR expression in the neurodegenerative process of PD using the MPTP-model. Mice with neuron-specific disruption of PPARc and PPARd coding regions were administered MPTP and measures of dopaminergic neuron survival assessed, thereby evaluating the role of these receptors in neuroprotection.
EXPERIMENTAL PROCEDURES Generation of conditional knock-outs
Mice null for one or both of PPARd and PPARc were generated using the Cre-lox technique, under the control of a neuronal promoter (Barak et al., 1999 (Barak et al., , 2002 . Fig. 1 . Immunolocalisation of PPARc and PPARd in the SNpc of genetically altered mice following MPTP treatment. Double immunofluorescence confirms the presence of PPARc (i-iii; green) and PPARd (iv-vi; green) with TH (red) in wild-type mice. The receptors remain visible when the Cre protein is expressed without the gene being excised (PPARc: vii-ix; PPARd: xvi-xviii). Fluorescence of PPARc is greatly reduced in the conditional knock-out (xix-xxi), while PPARd remains unaffected (xxii-xxiv). PPARd shows a stronger presence in its knock-out model but expression appears reduced (xxviii-xxx), while PPARc is unaffected (xxv-xxvii). In the double knock-out images expression of TH in dopaminergic neurons seems reduced and neurons show a change of morphology (xxxi-xxxiii and xxxiv-xxxvi). Scale bar = 50 lm. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
PPARd-null, PPARc-floxed and Nestin Cre mice were bred onto a wild-type C57Bl/6 background and crossbred to generate combinations of PPARc-null with or without Nestin Cre and PPARd-null with or without Nestin Cre. These generations were then cross-bred to produce a double knock-out: PPARc-null-PPARd-null with Nestin Cre (PPARc ckÀ/À /PPARd ckÀ/À ), before the resultant double-knock-out mice were bred together to increase the proportion of these with each generation. Nestin Cre-negative mice were added at alternate generations to maintain the optimum health of animals. It was ensured that littermates did not breed together.
Genotypes were confirmed by reverse transcription polymerase chain reaction (RT-PCR) using the Go Taq amplification system (Promega, Southampton, UK), as per manufacturer's instructions, following DNA extraction from ear clips and immunofluorescence staining of the receptors ( Figs. 1 and 2) .
Earclips of mice were taken and DNA samples extracted using DNAreleasy (Anachem, Luton, UK), following manufacturer's instructions. Genotyping was performed by RT-PCR using the Go Taq amplification system (Promega, Southampton, UK) as per manufacturer's instructions, with reaction mixture details in 
Animal treatments
Twelve-week-old male C57Bl/6 mice, PPARc and PPARd-genetically altered mice received intraperitoneal injections of MPTPÁHCl (30 mg/kg free base), dissolved in 0.9% saline solution, one injection per day for five consecutive days, before being sacrificed by decapitation 21 days after the last injection. Control mice received saline only. This treatment was in accordance with the published guidelines (JacksonLewis and Przedborski, 2007) . All procedures were in accordance with the Animals (Scientific Procedures) Act 1986 and were approved by the Home Office, Dundee, UK.
Immunohistochemistry and stereology
Brains were fixed and processed for immunostaining as described previously (Teismann et al., 2003; Sathe et al., 2012) . Primary and secondary antibodies used were rabbit anti-tyrosine hydroxylase (TH) (1:1000; Millipore, Watford, UK) and biotinylated goat anti-rabbit (1:200; Vector Laboratories, Peterborough, UK). Immunostaining was visualized with 3,3 0 -diaminobenzidine (SigmaAldrich, Poole, UK; 25 mg in 50 ml 0.1 M Tris GN pH 7.6 with 100 ll ammonium chloride (40 mg/200 ll Tris GN), 150 ll glucose oxidase (30 mg/10 ml Tris GN) and 400 ll glucose (200 mg/800 ll Tris GN)). Sections were counterstained with Nissl reagent (thionin). The total number of TH-positive neurons and Nissl-positive cells in the substantia nigra pars compacta (SNpc) was counted in the various groups of animals at 21 days after the last MPTP or saline injection using the unbiased optical fractionator method, as described previously (Teismann et al., 2003; Sathe et al., 2012) . Counting of TH-positive cells was performed using regular light microscopy (AxioImager M1, Carl Zeiss, Cambridge, UK) and the optical fractionator method (West, 1993 ) (Stereo Investigator Version 7, BMF Bioscience, Magdeburg, Germany), while the observer was blinded to the subjects' identity.
Striatal density of TH immunoreactivity was determined as described previously (Wu et al., 2002) and assessed on scans (Hewlett Packard Scanjet G3110, Bracknell, Berkshire, UK) of the sections using 
Immunofluorescence
Immunofluorescent staining was performed as described (Teismann et al., 2003; Sathe et al., 2012) . Sections were washed three times for 5 min with 0.1% Triton X in 0.1 M phosphate-buffered saline (PBS), before non-specific binding was blocked with 10% normal goat serum in 0.1 M PBS-Triton X (PBS-T). Sections were incubated overnight at 4°C in 0.1 M PBS-T with primary antibodies as follows: rabbit anti-TH (1:1000; Millipore), PPARc (1:100, Alexis Biochemicals, San Diego, CA, USA), PPARd (1:250, Abcam, Cambridge, UK). Following further washes, immunostaining was visualized with Alexa Fluor 488 anti-rabbit or anti-mouse (1:300; Molecular Probes, Eugene, OR, USA) or cy-3 anti-rabbit or antimouse (1:200; Jackson ImmunoResearch, West Grove, PA, USA) antibodies. After three final washes, sections were mounted on slides with Mowiol-DABCO. Immunostaining was visualized by confocal microscopy (LSM 510 or LSM 700, Carl Zeiss).
High performance liquid chromatography (HPLC)
HPLC with electrochemical detection was used to measure striatal levels of dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) using a method that has been described (Nuber et al., 2008) .
Statistical analysis
Data were analyzed in IBM SPSS Statistics Version 21 for Windows (Hampshire, UK). All values are expressed as the mean ± SEM. In the case of TH-numbers, Nissl counts and striatal optical density normal distribution of the data was tested and confirmed with the ShapiroWilk test. Homogeneity of variance was assessed by Levene's Test for Equality of Variance. For data sets, two-way analysis of variance (ANOVA) was used to assess differences among means, with genotype and treatment as the independent factor. When ANOVA showed significant differences, Tukey's post hoc testing was used to make comparisons between means. As not all groups are reported, we also assessed the differences among means with genotype as the independent factor in the two different treatment groups, followed by Newman-Keuls post hoc test. In the case of dopamine and DOPAC levels normal distribution of the data was tested and confirmed for logarithmized values with the Shapiro-Wilk test. Outliers were eliminated based on descriptive statistics performed by SPSS. Data are represented in non-log format for better understanding. When ANOVA showed significant differences, Tukey's post hoc testing was used to make comparisons between means. As not all groups are reported, we also assessed the differences among means with genotype as the independent factor in the two different treatment groups, followed by NewmanKeuls post hoc test. The null hypothesis was rejected at the 0.05 level.
RESULTS
To assess the precise contribution that the two receptors may have in a neuroprotective mechanism in PD, the transgenic mice were injected with the MPTP neurotoxin. Numbers of TH immunoreactive and Nissl-positive cells were stereologically counted (Fig. 3) . A two-way ANOVA was conducted to assess the effect of genotype and treatment on numbers of TH-immunoreactive neurons and Nissl-positive cells. There was a statistically significant interaction between genotype or treatment on numbers of TH-positive neurons as well as Nissl-positive cells. To assess the effect of genotype on MPTP-induced cell loss, a one-way ANOVA was performed and, as expected, MPTP caused a significant degeneration of TH-positive neurons in both wild-type (p < 0.001, a oneway ANOVA followed by Newman-Keuls post hoc test) and PPARc ckÀ/À /PPARd ckÀ/À mice (p < 0.01, a one-way ANOVA followed by Newman-Keuls post hoc test), compared to their saline-treated controls of the same genotype. MPTP also caused a significant degeneration of Nissl-positive cells in both wild-type (p < 0.001, a oneway ANOVA followed by Newman-Keuls post hoc test) and PPARc ckÀ/À /PPARd ckÀ/À mice (p < 0.001, a oneway ANOVA followed by Newman-Keuls post hoc test), To measure the impact on striatal fibers which innervate these bodies, TH density staining was assessed. MPTP reduced TH innervation of the striatum across all genotypes. The MPTP-treated double knockout brains have the lowest mean striatal density. Following the pattern of nigral TH immunoreactivity (Fig. 4A, B) , the striatal densities of floxed and single PPARc or PPARd knock-out mice appear higher, but the differences are not significant.
Levels of striatal monoamine were determined using HPLC analysis (Fig. 4C, D) . Across values of dopamine and its metabolite DOPAC, significant differences were not found between MPTP-treated PPARc ckÀ/À /PPARd ckÀ/À mice and those with one or both of PPARc and PPARd genes left intact, but the mean value for the double knock-out mice remains lowest of all treatment groups. There was a statistically significant interaction between genotype or treatment on striatal dopamine content (a two-way ANOVA followed by Tukey post hoc test). To assess the effect of genotype alone on MPTP-treatment a one-way-ANOVA was performed. There are significant differences in dopamine levels between saline-treated wild-type (p < 0.001, a one-way ANOVA followed by NewmanKeuls post hoc test), PPARc ck and PPARc ckÀ/À (p < 0.01, a one-way ANOVA followed by NewmanKeuls post hoc test) and their MPTP-infused littermates, while DOPAC levels are diminished when MPTP is administered to wild-type and PPARc ck mice compared to their saline-treated equivalents (p < 0.01, a one-way ANOVA followed by Newman-Keuls post hoc test).
Staining was performed on mice treated with MPTP of all genotypes to give an indication of knock-out success (Fig. 1) . Both receptors are clearly visible following double immunofluorescence of PPARc (i-iii; green) or PPARd (iv-vi; green) with TH (red) in wild-type mice. PPARc is present in a peri-nuclear location and PPARd is found in the nuclei of neurons. This presence is maintained when the Cre recombinase protein is expressed without the gene being excised (PPARc: viiix; PPARd: xxii-xxiv). When mice null for the gene are compared with Cre + mice, the expression of the relevant gene is diminished. Fluorescence of PPARc is greatly reduced in conditional knock-out mice (xiii-xv), while PPARd remains unaffected (xvi-xviii). PPARd appears to remain at a relatively high expression level in its knock-out model (xxviii-xxx), but at a diminished level, while PPARc is unaffected (xxv-xxvii). This may be due to a form of Cre mosaicism in this particular group, difficult to detect with standard genotyping. In the double knock-out images, both receptors, particularly PPARc, show greatly reduced expression and TH cell 
DISCUSSION
This study aimed to assess the contributions of PPARc and PPARd in MPTP toxicity. Previous work through the use of receptor-specific ligands has delineated the neuroprotective effects that activation of these receptors has in several models of neurodegeneration. There is evidence that they are likely to work through negative modulation of immune responses through the inhibition of pro-inflammatory cytokine release (Bishop-Bailey and Bystrom, 2009). To consider the relative roles of the two receptor subtypes and their contributions to such a mechanism we generated single and double knock-out mice of both PPAR isoforms. It was necessary to generate double knockouts of PPARc and PPARd as PPAR isoforms are known to be subject to functional compensation (Patsouris et al., 2006) . Importantly, this compensatory change is known to occur in neurons (Gonzalez-Aparicio et al., 2011) . Conditional knock-outs were required as a complete knock-out of either receptor is lethal. Studies by Barak and colleagues have investigated the viability of PPARc À/À and PPARd À/À mice (Barak et al., 1999 (Barak et al., , 2002 . Inducing PPARc deficiency through homologous recombination causes death at two independent developmental points, both of which result in embryonic death by day 10 (Barak et al., 1999) . Similarly, PPARd-deficiency results in a high degree of embryonic lethality (over 90%) with surviving mice smaller then wild-type counterparts, while offspring of these mice typically do not survive to full # p < 0.05, ### p < 0.001, compared to saline-treated group of same genotype (a one-way ANOVA followed by Newman-Keuls post hoc test).
term due to placental defects (Barak et al., 2002) . It was subsequently found that PPARd is a critical molecular signaling link during the processes of maternal implantation and decidualization, with embryonic expression of the receptor required for placentation (Wang et al., 2007) . The Cre-lox P method, a technique pioneered by Sauer and Henderson (1988) , was utilized to produce tissuespecific knock-outs of the gene products to avoid the lethality which affects complete PPARc and PPARd knock-outs. Still, by using the knockout technique, mutation occurs systemically. Specifically silencing PPARd and/or PPARc in the SNpc or striatum could be a further useful approach to delineate the function of these PPAR isoforms.
Offspring of several genotypes were administered MPTP before assessing neurodegeneration. Numbers of TH-positive cells were lowest in the PPARc ckÀ/À / PPARd ckÀ/À group of mice, although this number did not vary significantly from that shown by single knock-out or floxed mice. The relatively even number of cells across the PPARc ckÀ/À and PPARd ckÀ/À groups may indicate equally significant contributions to processes underlying overall neuron survival from activation of these receptor subtypes. Furthermore, a lower mean TH-positive cell count among PPARc ckÀ/À /PPARd ckÀ/À mice potentially indicates a degree of functional compensation that may acquire increased importance when expression of one receptor is lower than physiological levels. As PPARc and PPARd can also be expressed by glial cells, it seems more likely that the expression of PPARs on these cells is more relevant to the overall effect of PPAR-mediated effects in the MPTP-model. The trend observed in neuron cell bodies was adhered to in other measurements of dopaminergic cell loss. The density of TH-positive fiber projection to the striatum showed an identical pattern to that of nigral TH-positive neurons, while striatal dopamine and DOPAC levels, measured by HPLC, demonstrated similar results. All genotypes express lower dopamine levels, although not to a significant extent. This could be an effect of the genes involved which, despite not being active, might still have an impact on overall dopamine content. Wildtype mice show similar levels of TH-positive cells compared to the single receptor knock-out or floxed mice. This may be due to a functional compensation of the PPAR isoforms to levels where physiological neuroprotective mechanisms are maintained. Further studies should address whether the observed changes also translate to functional changes using appropriate behavioral tests.
It has been shown that heterozygous PPARd mice maintain levels of protein relative to that of wild-type mice despite having approximately half the PPARd mRNA, thereby indicating PPARd has a vital function in the basal activity of neurons (Martin et al., 2013) . The importance of PPARd has been proposed previously, with evidence the isoform acts as a 'gateway receptor', as stable expression of the PPARd inhibits that of PPARc and modulates its function (Shi et al., 2002) . As noted above, the levels of dopaminergic cell survival were relatively equal in PPARc ckÀ/À and PPARd ckÀ/À mice. This indicates that PPARd may play no particular importance in the regulation of inflammation over the PPARc isoform. However, there is an absence of statistical significance in the results, likely due in part to the low numbers of PPARc ckÀ/À /PPARd ckÀ/À , a result of the difficulty in producing these mice in the time-frame of the study. The work, nonetheless, provides compelling initial genetic evidence that backs up pharmacological studies supporting the importance in PPAR activation in neuronal survival. Pharmacological antagonism of both receptors has independently proven to reduce cell survival. The selective PPARd antagonist GSK0660 can exacerbate 1-methyl-4-phenylpyridinium (MPP) + -induced cell death in vitro (Martin et al., 2013) . A selective antagonist of PPARc, bisphenol A diglycidyl ether, causes deteriorating clinical performance in a model of multiple sclerosis (Raikwar et al., 2005) . Another antagonist at this receptor subtype, GW9662, augmented MPTP-induced loss of TH-positive neuron in mice , demonstrating that activation of these receptors may be important in protection against inflammatory insult. Indeed, there are many studies providing signs that PPARc and PPARd activation is important in mediating neuroprotection. Investigations of the PPARc agonists pioglitazone (Breidert et al., 2002; Dehmer et al., 2004) , rosiglitazone (Schintu et al., 2009; Martin et al., 2012; Pisanu et al., 2014) and the non-thiazolidinedione MDG548 (Lecca et al., 2015) have provided evidence that these agents can attenuate MPTP-induced neuronal loss in the SNpc. The thiazolidinedione pioglitazone is able to restore mitochondrial function following administration of the bacterial endotoxin LPS in rats (Hunter et al., 2007) . This particular action may be through an upregulation of anti-apoptotic protein Bcl-2 (Fuenzalida et al., 2007) , which can inhibit the opening of mitochondrial permeability pores (Zorov et al., 2009) . Furthermore, additional experiments need to demonstrate if PPAR agonists provide protection in a regional-specific model of PD, such as the lentiviralbased delivery of a-synuclein (Lo et al., 2002) , thus demonstrating the relevance of PPARs as a potential neuroprotective therapy. It would also be useful to assess the impact of silencing these receptors in a specific region, such as SNpc or even the striatum.
In all cases protection occurs alongside a reduction in the immune response as microglial and astrocyte activation is reduced. PPARc agonists can reduce inflammatory responses including production of TNFa and inducible nitric oxide synthase (iNOS) (Breidert et al., 2002) . Both these processes have been implicated in the death of dopaminergic neurons (Boka et al., 1994; Hunot et al., 1996) . In addition, PPARc activation led to a reduction of MPTP-induced nitrotyrosine levels, a marker for NO-mediated damage (Dehmer et al., 2004) , and reduced MPTP-mediated increase in iNOS expression (Lecca et al., 2015) . A possible antioxidant role of PPARc activation is supported by our own group, as we demonstrated that rosiglitazone attenuates reactive oxygen species (ROS) formation induced by MPP + in vitro . This may be through upregulation of superoxide dismutase (SOD) and catalase expression (Jung et al., 2007) . Alterations in PPAR expression also supplement the hypothesis that the presence of the PPARc and PPARd subtypes together is important in neuroprotection. Both the mRNA and protein levels of PPARc in the ventral midbrain are upregulated 7 days after MPTP treatment . Similarly, PPARd mRNA and protein levels show an immediate upregulation in the striatum (Martin et al., 2013) . These expression alterations may represent an endogenous defence mechanism against the inflammatory and oxidative insults of MPTP -a mechanism that PPARc ckÀ/À /PPARd ckÀ/À mice are likely devoid of, leading to reduced neuron survival. Furthermore, endogenous ligands of the PPARs may have a role. The structure of these receptors allow for the binding of an array of ligands, including fatty acids, eicosanoids and steroids. The impact these could have on this mechanism is not currently known.
It would be interesting to investigate the protective abilities of PPAR agonists in knock-out animals to test whether the benefits shown by these agents are dependent upon receptor activation or can be initiated independently of the receptor.
Biological effects following administration of agonists that are not dependent upon PPARc activation, such as antioxidant benefits, have a significant impact upon neuroprotection (Davies et al., 2001; Chintharlapalli et al., 2005; Wang et al., 2011; Martin et al., 2012) . The use of agonists may have an influence on cellular metabolic function as pioglitazone could increase glucose uptake by cells, thereby increasing their resistance to MPTP (Breidert et al., 2002) . It remains to be seen whether these same pro-inflammatory mediators are inhibited without the direct action of the ligand, but this study further underlines the importance of PPAR pathways in models of neuronal degeneration.
CONCLUSION
Neuronal PPARc or PPARd does not seem to counteract MPTP-induced toxicity. Different aspects need to be taken into account to explain the findings. The results might be due to the fact that ablation of the neuronal receptors was not 100% complete, but were below the level to be picked up using PCR and immunohistochemistry.
Since PPARs are also expressed on glial cells, it may be argued that the main protective role of PPARs is played by glial receptors rather than neuronal, an aspect which needs further investigation.
